Price (delayed)
$0.5125
Market cap
$9.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
$8.44M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
There are no recent dividends present for BCTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.